ストックスクリーナーアプリを入手
0.9945
0.45%
0.0045
前日終値:
$0.99
開ける：
$0.9824
24時間の取引高:
552.65K
Relative Volume:
0.58
時価総額：
$45.35M
収益：
$5.12M
当期純損益:
$-67.00M
株価収益率:
-1.8832
EPS:
-0.5281
ネットキャッシュフロー:
$-38.94M
1週間 パフォーマンス:
+19.32%
1か月 パフォーマンス:
-37.45%
6か月 パフォーマンス:
-89.01%
1年 パフォーマンス:
-72.75%
1日の値動き範囲:
$0.9602
$1.02
1週間の範囲:
$0.8031
$1.09
52週間の値動き範囲:
$0.7043
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| VRCA | 0.9945 | 45.35M | 5.12M | -67.00M | -38.94M | -0.5281 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Watkins Advises on Verrica Pharmaceuticals Inc.’s Public Offering - Latham & Watkins LLP
Chester County firm expects to raise $42M after trimming staff and naming new CEO - The Business Journals
Verrica Pharmaceuticals stock dips after pricing $42M securities offering - MSN
Verrica Prices of $42 Million Public Offering - citybiz
VRCAVerrica Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewswire
Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | VRCA Stock News - StockTitan
Form 424B5 Verrica Pharmaceuticals - StreetInsider.com
Verrica Pharmaceuticals announces proposed public offering - MSN
Verrica Announces Proposed Public Offering - The Manila Times
Verrica Pharmaceuticals Announces Public Offering of Stock and Warrants with Jefferies | VRCA Stock News - StockTitan
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock By Investing.com - Investing.com UK
Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World
Verrica downgraded to sector perform by RBC Capital - MSN
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Verrica Pharmaceuticals Announces Leadership Transition and Financial Results for Q3 2024 - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to "Neutral" at HC Wainwright - MarketBeat
RBC Capital Downgrades Verrica Pharmaceuticals (VRCA) - MSN
Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com
Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com South Africa
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring - TipRanks
Botanix Pharmaceuticals Poised for Market Impact with Sofdra Launch - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):